Accessibility Menu
Evaxion A/s logo

Evaxion A/s(NASDAQ) EVAX

Market Cap$25.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-99%
1 Year+6%
1 Month-5%
$2.99
+7.17%
+0.20Today
Pre market$3.16+$0.17 (+5.69%)
Evaxion A/s last closing stock price
MetricPriceDate
Last closeUSD 3.102026-08-07
Evaxion A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.93%USD 2.822026-07-31
1 month-4.62%USD 3.252026-07-08
3 month-28.57%USD 4.342026-05-08
Year to date-35.01%USD 4.772025-12-31
1 year+5.8%USD 2.932025-08-07
3 year-93.67%USD 49.002023-08-08
5 year-98.96%USD 297.002021-08-06
Since inception-99.37%USD 494.502021-02-05

Evaxion A/s Financials at a Glance

Market Cap

$25.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.53M

Net Income (TTM)

-$9.76M

EPS (TTM)

-$1.38

P/E Ratio

-2.24

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Price

$2.99

Volume

28,372.743

Open

$3.10

Previous Close

$3.10

Daily Range

$3.08 - $3.32

52-Week Range

$2.52 - $12.15

Estimated Earnings Date

Aug 13, 2026

EVAX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evaxion A/s

Evaxion Biotech A/S is a clinical-stage biotechnology firm focused on developing artificial intelligence-driven immunotherapies. The company targets cancers, bacterial infections, and viral diseases with a promising pipeline of innovative therapies.

Products and Services
  • EVX-01: Phase IIb cancer immunotherapy for metastatic melanoma
  • EVX-02: DNA-based immunotherapy in Phase IIa trials for adjuvant melanoma
  • EVX-B1, EVX-B2, EVX-V1: Pre-clinical vaccine candidates for bacterial and viral pathogens
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical trials
  • Potential market expansion as AI-driven therapies gain traction
  • Increased focus on oncology and infectious diseases enhances growth prospects
Financial Highlights
  • Recent quarterly net income of -$3.63 million reflects ongoing R&D investments
  • Trailing twelve months (TTM) revenue of $7.49 million indicates market interest
  • Cash and cash equivalents of $18.44 million provide operational runway
Evaxion Biotech A/S is positioned at the forefront of biotechnology innovation, leveraging artificial intelligence to enhance immunotherapy development. The company's focus on oncology and infectious diseases aligns with growing market demands for effective treatments. With a robust pipeline and significant R&D investments, Evaxion aims to capitalize on emerging opportunities in the healthcare sector. Recent financial data highlights the company's commitment to advancing its product offerings, while maintaining a solid cash position to support ongoing operations.
AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

46

CEO

Helena Katrina Tayton-Martin, PhD, MBA

Website

www.evaxion-biotech.com

Headquarters

Horsholm, ND 2970, DK

EVAX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-122.05%

Net Income Margin

-129.63%

Return on Equity

-73.56%

Return on Capital

-37.62%

Return on Assets

-41.28%

Earnings Yield

-44.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.34M

Volume

28.37K

Avg. Volume

23.67K

Financials (TTM)

Gross Profit

$7.53M

Operating Income

-$9.19M

EBITDA

-$10.87M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$18.44M

Total Debt

$0.00

Evaxion A/s Performance Analysis

Evaxion A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 73,112N/A
20242024-12-31USD 3,338,6364466.5%
20252025-12-31USD 7,551,041126.2%
Evaxion A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3020148.6%
Q42025-12-31-100.0%
Q12026-03-31N/A
Evaxion A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -49.03-22.0%
20232023-12-31USD -40.53-17.3%
20242024-12-31USD -9.83-75.7%
20252025-12-31USD -1.21-87.7%
Evaxion A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-780.0%
Q32025-09-30195.5%
Q42025-12-31-121.2%
Q12026-03-3150.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$25.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$562.06K

N/A

Employees

46

N/A

Net Income

-$3.63M

-129.7%

EBITDA

-$3.51M

-155.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$18.44M

+3.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-41.28%

N/A

Return on Invested Capital

-38.87%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BTAIBioXcel Therapeutics, Inc.
$0.92+1.47%
CELUCelularity Inc.
$0.71+1.26%
MURAMural Oncology plc
$2.04+0.00%
GBIOGeneration Bio Co.
$5.34+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$132.86-0.00%
ACHRArcher Aviation
$6.10+0.09%
NVDANvidia
$218.69-0.02%
INTCIntel
$98.63-0.03%

Questions About EVAX

What is the current price of Evaxion A/s?

Evaxion A/s is trading at $3.14 per share.

What is the 52-week range for Evaxion A/s?

Over the past 52 weeks, Evaxion A/s has traded between $2.52 and $12.15.

How much debt does Evaxion A/s have?

As of the most recent reporting period, Evaxion A/s reported total debt of $7.50M.

How much cash does Evaxion A/s have on hand?

Evaxion A/s reported $18.44M in cash and cash equivalents in its most recent financial results.

What is Evaxion A/s’s dividend yield?

Evaxion A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services